Molecular and Cellular Immunology Core

分子和细胞免疫学核心项目总结 作为流式细胞术、细胞分类和各种免疫学服务的独特研究资源， 夏威夷大学(UH)和整个夏威夷州的分子和细胞免疫学(MCI)核心 对提高研究生产率、增强研究竞争力和 在科布雷第一阶段和第二阶段期间提高赠款成功。外部资助的研究严重依赖 在MCI核心上，这一需求预计将在第三阶段科布雷期间和之后增长。 第三阶段Cobre的目标是促进MCI核心向可持续的最先进水平的转变 能够支持对新的、新兴的和重新出现的传染病进行高水平研究的核心设施 疾病以及科学研究的其他领域将通过以下方式实现：(1)加强和精简核心 业务；(2)扩大和多样化用户基础、能力、能力和覆盖范围；(3)加强 核心基础设施。对于目标1，将进行需求评估和用户满意度调查，以 确保核心运营的效率和有效性。同时，指导和培训现有的和潜在的 用户将得到更好的整合，并将与传染病研究培训方案建立伙伴关系 疾病和免疫学。对于目标2，外展和营销活动将扩展到其他地方 UH系统之外的学术机构、生物技术公司和医院，以及强大的合作伙伴关系 与位于其他COBRE、INBRE和IDEA-CTR计划中的类似核心组成，以实现增长和多样化 核心用户基础，并获得新的工具和技术。此外，MCI核心将利用现有的 亚太地区研究培训实验室的基础设施，以促进国际合作 研究。对于目标3，将在第三阶段制定可持续性和分阶段实施的业务计划 科布雷时期，利用多种方式的内部和外部支持来维持核心。周期性的 评价和审查核心的财政健康状况将有助于对影响的关键因素进行必要的重组 偿付能力，以指导在第三阶段Cobre支持之后维持核心的努力。 预计MCI核心将实现上述每一项具体目标。50,000美元的坚定承诺 在第三阶段科布尔期之后的五年内，每年由JABSOM主任提供重要的 在这种竞争和不确定的融资环境中对冲不确定的收入流，并将确保 继续核心业务，有可能提高赠款成功率和核心可持续性。

Project Summary for the Molecular and Cellular Immunology Core As the singular research resource for flow cytometry, cell sorting and myriad immunological services at the University of Hawaii (UH) and in the entire State of Hawaii, the Molecular and Cellular Immunology (MCI) Core has had a significant impact on increasing research productivity, enhancing research competitiveness and heightening grants success during COBRE Phases I and II. Extramurally funded research is heavily dependent on the MCI Core, and the need is anticipated to grow during and beyond the Phase III COBRE period. The Phase III COBRE objective of facilitating the transition of the MCI Core into a sustainable state-of-the-art core facility capable of supporting high-caliber research on new, emerging and re-emerging infectious diseases, as well as other fields of scientific inquiry, will be achieved by (1) enhancing and streamlining core operations; (2) growing and diversifying the user base, capability, capacity and reach; and (3) strengthening the core infrastructure. For Aim 1, needs assessments and user satisfaction surveys will be conducted to ensure efficiency and effectiveness of core operations. Also, mentoring and training of current and prospective users will be better integrated, and partnerships will be formed with research training programs in infectious diseases and immunology. For Aim 2, outreach and marketing activities will be expanded to other local academic institutions, biotech companies and hospitals beyond the UH System, and strong partnerships will be formed with similar cores located in other COBRE, INBRE and IDeA-CTR programs to grow and diversify the core user base and to acquire new tools and techniques. Also, the MCI Core will leverage the existing infrastructure of research training laboratories in the Asia-Pacific region to facilitate international collaborative research. And for Aim 3, sustainability and phased-in business plans will be developed during the Phase III COBRE period to draw on multiple avenues of intramural and extramural support to sustain the Core. Periodic evaluation and review of the Core's fiscal health will allow necessary restructuring of the key elements affecting solvency to guide efforts to sustain the Core beyond Phase III COBRE support. The MCI Core is expected to achieve each of the above-stated specific aims. A strong commitment of $50,000 per year for five years beyond the Phase III COBRE period, by the JABSOM Dean, will provide an important hedge against uncertain revenue streams during this competitive and uncertain funding climate and will ensure continued core operations, with the prospect of increased grants success and core sustainability.